📊 ACHV Key Takeaways
Is Achieve Life Sciences, Inc.. (ACHV) a Good Investment?
Achieve Life Sciences is a pre-revenue or near-zero revenue company with significant operating losses (-$39.8M) and negative free cash flow (-$31.5M), indicating the company is in early-stage development with no path to profitability yet visible. While the company maintains adequate liquidity ($31.9M cash) and low leverage, the burn rate relative to cash reserves suggests runway of approximately 12 months, requiring near-term capital raises or major commercialization progress.
Achieve Life Sciences has no revenue, deeply negative earnings, and substantial operating cash burn, so its current fundamentals depend almost entirely on external financing rather than business self-sufficiency. The balance sheet is relatively clean with strong liquidity and no meaningful debt, but absent commercialization progress or a sharp reduction in burn, financial quality remains weak.
Why Buy Achieve Life Sciences, Inc.. Stock? ACHV Key Strengths
- Strong liquidity position with $31.9M in cash equivalents
- Low leverage with 0.00x debt-to-equity ratio
- Adequate working capital with 5.14x current ratio providing short-term financial flexibility
- Diagnostic substances sector offers potential for high-margin products upon commercialization
- Strong liquidity position with $31.93M in cash and current ratio of 5.14x
- No meaningful long-term debt, limiting balance-sheet leverage risk
- Very low capital expenditure needs keep cash usage focused on core development activities
ACHV Stock Risks: Achieve Life Sciences, Inc.. Investment Risks
- Zero revenue generation indicates complete lack of commercialization despite company history
- Severe operating losses of $39.8M with negative $31.5M operating cash flow
- Cash runway approximately 12 months at current burn rate without revenue improvement
- Negative ROE (-119%) and ROA (-76.8%) indicate substantial destruction of shareholder value
- No demonstrated ability to generate cash from core operations
- Requires significant capital infusion or dramatic operational turnaround to survive
- No revenue base, leaving the company fully reliant on capital markets or partnerships
- Large recurring losses with net income of -$39.99M and ROE of -119.0%
- Negative free cash flow of -$31.51M raises runway and dilution risk if funding needs persist
Key Metrics to Watch
- Quarterly revenue achievement and customer acquisition
- Operating cash flow trend and cash burn rate trajectory
- Cash reserves and timing of potential capital raises
- Product development milestones and regulatory approvals
- Insider buying/selling patterns indicating management confidence
- Quarterly operating cash burn relative to cash on hand
- Any transition from zero revenue to sustainable collaboration, milestone, or product revenue
Achieve Life Sciences, Inc.. (ACHV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.14x current ratio provides a solid financial cushion.
ACHV Profit Margin, ROE & Profitability Analysis
ACHV vs Healthcare Sector: How Achieve Life Sciences, Inc.. Compares
How Achieve Life Sciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Achieve Life Sciences, Inc.. Stock Overvalued? ACHV Valuation Analysis 2026
Based on fundamental analysis, Achieve Life Sciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Achieve Life Sciences, Inc.. Balance Sheet: ACHV Debt, Cash & Liquidity
ACHV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Achieve Life Sciences, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.50 indicates the company is currently unprofitable.
ACHV Revenue Growth, EPS Growth & YoY Performance
Achieve Life Sciences, Inc.. Dividends, Buybacks & Capital Allocation
ACHV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Achieve Life Sciences, Inc.. (CIK: 0000949858)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACHV
What is the AI rating for ACHV?
Achieve Life Sciences, Inc.. (ACHV) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACHV's key strengths?
Claude: Strong liquidity position with $31.9M in cash equivalents. Low leverage with 0.00x debt-to-equity ratio. ChatGPT: Strong liquidity position with $31.93M in cash and current ratio of 5.14x. No meaningful long-term debt, limiting balance-sheet leverage risk.
What are the risks of investing in ACHV?
Claude: Zero revenue generation indicates complete lack of commercialization despite company history. Severe operating losses of $39.8M with negative $31.5M operating cash flow. ChatGPT: No revenue base, leaving the company fully reliant on capital markets or partnerships. Large recurring losses with net income of -$39.99M and ROE of -119.0%.
What is ACHV's revenue and growth?
Achieve Life Sciences, Inc.. reported revenue of $0.0.
Does ACHV pay dividends?
Achieve Life Sciences, Inc.. does not currently pay dividends.
Where can I find ACHV SEC filings?
Official SEC filings for Achieve Life Sciences, Inc.. (CIK: 0000949858) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACHV's EPS?
Achieve Life Sciences, Inc.. has a diluted EPS of $-0.99.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACHV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Achieve Life Sciences, Inc.. has a SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACHV stock overvalued or undervalued?
Valuation metrics for ACHV: ROE of -119.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACHV stock in 2026?
Our dual AI analysis gives Achieve Life Sciences, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACHV's free cash flow?
Achieve Life Sciences, Inc..'s operating cash flow is $-31.5M, with capital expenditures of $21.0K.
How does ACHV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -119.0% (avg: 15%), current ratio 5.14 (avg: 2).